- Mr. Glover will be joining four other life science
executives in a General Session titled, CEO Panel: Learn from the
experts
- ZyVersa is a clinical stage biopharmaceutical company with
two licensed proprietary product platforms targeting renal and
inflammatory diseases
- ZyVersa and Larkspur Health entered into a definitive
business combination agreement on July 20,
2022, which is expected to be completed in fourth quarter of
2022
- Combined company expected to be named ZyVersa Therapeutics,
Inc. and listed on NASDAQ under ticker "ZVSA"
WESTON,
Fla. and BRIDGEWATER,
N.J., Oct. 28, 2022 /PRNewswire/ -- ZyVersa
Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop drug therapies that address unmet medical
needs in the areas of renal and inflammatory diseases, and Larkspur
Health Acquisition Corp. (NASDAQ: LSPR) ("Larkspur"), a blank-check
special purpose acquisition company, are pleased to announce that
Stephen C. Glover, ZyVersa's
Co-Founder, Chief Executive Officer, and Chairman, is an invited
speaker at BioFlorida's 2022 Annual Conference being held in
Miami, Florida on November 2-4, 2022.
Hear what ZyVersa's CEO has to say about
building an innovative, successful biopharma company at BioFlorida
2022
Mr. Glover will be joining four other life science executives in
a General Session titled, CEO Panel: Learn from the Experts.
Mr. Glover will share his experience and insights in building an
innovative and successful biopharmaceutical company.
The CEO Panel will take place:
- Date: Friday, November 4,
2022
- Time: 9:00 – 9:40am ET
- Event Registration Link: BioFlorida Annual Conference
2022
To learn more about ZyVersa, cholesterol efflux mediator (VAR
200), and inflammasome ASC inhibitor (IC 100), request a one-on-one
meeting with Mr. Glover at ir@zyversa.com, or visit
www.zyversa.com.
About ZyVersa Therapeutics,
Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop drug
therapies that address unmet medical needs in the areas of renal
and inflammatory diseases. ZyVersa's development pipeline includes
phase 2a ready VAR 200, a cholesterol efflux mediator for treatment
of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa
believes VAR 200 has the potential to treat other glomerular
diseases, including Alport syndrome and diabetic kidney disease.
ZyVersa's development pipeline also includes IC 100, a novel
inflammasome ASC inhibitor being developed to treat a multitude of
inflammatory diseases. For more information, please visit
www.zyversa.com.
About Larkspur Health Acquisition
Corp.
Larkspur is a Special Purpose Acquisition Company (SPAC) formed
to identify a biopharmaceutical company that can develop and thrive
as a newly formed public company and benefit from Larkspur's
operational expertise and a significant infusion of capital. Each
of Larkspur's management team and board of directors have been
former management and executive leadership of private and public
biopharmaceutical companies and have over 50+ years of aggregate
investment and operational experiences. The team strongly believes
in the growth opportunities in the biotechnology industry. They are
experienced operators who seek to partner with top innovators and
thinkers in the biopharmaceutical field. As operators, their
entrepreneurial approach enables support for management teams in
making impactful decisions with an eye toward growth and
operational excellence. For more information, please visit
www.lsprhealth.com.
Forward Looking
Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws with respect to
certain product candidates that will be the subject of a proposed
transaction between Larkspur Health Acquisition Corp. ("Larkspur"),
and ZyVersa Therapeutics, Inc ("ZyVersa"). All statements other
than statements of historical facts contained in this press
release, including statements regarding Larkspur or ZyVersa's
future results of operations and financial position, the amount of
cash expected to be available to ZyVersa after the closing and
giving effect to any redemptions by Larkspur's stockholders,
ZyVersa's business strategy, prospective product candidates,
product approvals, research and development costs, timing and
likelihood of success, plans and objectives of management for
future operations, future results of current and anticipated
product candidates, and expected use of proceeds, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believe," "project,"
"expect," "anticipate," "estimate," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including, but not limited to, the
following risks relating to the proposed transaction: the
occurrence of any event, change or other circumstances that could
give rise to the termination of the Business Combination Agreement;
the risk that the transaction may not be completed in a timely
manner or at all, which may adversely affect the price of
Larkspur's securities; the occurrence of any event, change or other
circumstances that could give rise to the termination of the Merger
Agreement; the inability to complete the Transactions, including
due to failure to obtain approval of the shareholders of Larkspur
or other conditions to closing in the Merger Agreement; the
inability to obtain or maintain the listing of Larkspur's common
stock on NASDAQ following the Transactions; the risk that the
Transactions disrupt current plans and operations of ZyVersa as a
result of the announcement and consummation of the Transactions;
the ability to recognize the anticipated benefits of the
Transactions, which may be affected by, among other things,
competition, the ability of the combined company to grow and manage
growth economically and hire and retain key employees; the risks
that ZyVersa's product candidates in development fail clinical
trials or are not approved by the U.S. Food and Drug Administration
or other applicable authorities; costs related to the Transactions;
changes in applicable laws or regulations; the possibility that
Larkspur or ZyVersa may be adversely affected by other economic,
business, and/or competitive factors; and other risks and
uncertainties to be identified in the proxy statement/prospectus
(when available) relating to the Transactions, including those
under "Risk Factors" therein, and in other filings with the SEC
made by Larkspur.. Moreover, ZyVersa operates in a very competitive
and rapidly changing environment. Because forward-looking
statements are inherently subject to risks and uncertainties, some
of which cannot be predicted or quantified and some of which are
beyond Larkspur's and ZyVersa's control, you should not rely on
these forward-looking statements as predictions of future events.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and except as required by law. Larkspur and ZyVersa
assume no obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Neither Larkspur nor ZyVersa gives any
assurance that either Larkspur or ZyVersa or the combined company
will achieve its expectations.
Important Information for
Investors and Stockholders and Where to Find It
Larkspur intends to file a registration statement on Form S-4
that will include a proxy statement with respect to the stockholder
meeting of Larkspur and a prospectus with respect to securities of
the combined company. After the registration statement is declared
effective by the SEC, the proxy statement/prospectus will be sent
to all Larkspur and ZyVersa stockholders. Larkspur will also file
other documents regarding the proposed business combination with
the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND
SECURITIES HOLDERS OF LARKSPUR AND ZYVERSA ARE URGED TO READ THE
PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED
OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED
BUSINESS COMBINATION AS THEY BECOME AVAILABLE SINCE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS
COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS
COMBINATION.
Investors and securities holders will be able to obtain free
copies of the proxy statement/prospectus and all other relevant
documents filed or that will be filed with the SEC by Larkspur
through the website maintained by the SEC at https://sec.gov/. In
addition, the documents filed by Larkspur may be obtained free of
charge from Larkspur's website at www.lsprhealth.com or by written
request to info@lsprhealth.com.
Participants in the
Solicitation
Larkspur, ZyVersa, and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from Larkspur's stockholders in connection with the
proposed transaction. Information about Larkspur's directors and
executive officers and their ownership of Larkspur's securities is
set forth in Larkspur's Annual Report on Form 10-K for the year
ended December 31, 2021, filed with
the SEC, as modified or supplemented by any Form 3 or Form 4 filed
with the SEC since the date of such filing. Other information
regarding the interests of the participants in the proxy
solicitation will be included in the proxy statement/prospectus
pertaining to the proposed Transactions when it becomes
available.
No Offer or Solicitation
This release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction. No offer of securities shall be made except by means
of a prospectus.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zyversa-therapeutics-ceo-stephen-c-glover-is-invited-speaker-at-bioflorida-2022-annual-conference-301661951.html
SOURCE ZyVersa Therapeutics, Inc.; Larkspur Health Acquisition
Corp.